180 Life Sciences Corp. (NASDAQ:ATNF) Short Interest Update

180 Life Sciences Corp. (NASDAQ:ATNF) was the recipient of a large decline in short interest in November. As of November 15th, there was short interest totalling 90,800 shares, a decline of 34.9% from the October 31st total of 139,400 shares. Currently, 18.5% of the shares of the stock are sold short. Based on an average daily volume of 1,970,000 shares, the short-interest ratio is presently 0.0 days.

180 Life Sciences Stock Down 0.5 %

NASDAQ ATNF opened at $2.19 on Friday. 180 Life Sciences has a twelve month low of $1.16 and a twelve month high of $17.75. The stock has a 50-day moving average of $2.72 and a 200 day moving average of $2.16.

About 180 Life Sciences

180 Life Sciences Corp., a clinical stage biotechnology company, focuses on developing therapeutics for unmet medical needs in chronic pain, inflammation, fibrosis, and other inflammatory diseases. The company product development platforms includes fibrosis and anti-tumor necrosis factor (anti-TNF) platform, which has completed Phase IIb clinical trials that focuses on fibrosis and anti-TNF; Synthetic Cannabidiol (CBD) Analogs platform, which are synthetic pharmaceutical grade molecules close or distant analogs of non-psychoactive cannabinoids, such as CBD for the treatment of inflammatory diseases and pain; and a7nAChR platform, an immune suppressive, which is under preclinical trails that focuses on alpha 7 nicotinic acetylcholine receptor.